Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
Xeris Pharmaceuticals , Inc. (NASDAQ:XERS) has reached a new 52-week high, with its stock price soaring to $4.69. This milestone reflects a significant surge in the company’s stock value, marking a remarkable 114% increase over the past year. The company, now valued at $714 million, has demonstrated strong momentum with revenue growth of nearly 24% in the past year. According to InvestingPro analysis, the stock’s RSI indicates overbought conditions, while analyst targets range up to $8 per share. Investors have shown increased confidence in Xeris Pharmaceuticals, as the company continues to make strides in the biopharmaceutical sector, developing innovative therapies that address unmet medical needs. The 52-week high serves as a testament to the company’s growing market presence and the positive reception of its products and research within the healthcare investment community. Discover more technical indicators and 8 additional key insights with InvestingPro’s comprehensive analysis tools.
In other recent news, Xeris Pharmaceuticals reported impressive fourth-quarter 2024 earnings, surpassing analyst expectations. The company achieved an earnings per share (EPS) of -0.03, beating the forecasted -0.06, and reported revenues of $60.1 million, exceeding the anticipated $55.99 million. For the full year, Xeris generated $203.1 million in total revenue, marking a 24% growth compared to the previous year. The company projects strong revenue growth for 2025, with expectations between $255 million and $275 million, indicating a potential 30% increase. Additionally, H.C. Wainwright recently raised Xeris’ stock price target to $8.00 from $6.60, maintaining a Buy rating, citing the company’s strong 2025 guidance and a clear path to cash flow breakeven. The firm’s analysis highlighted Xeris’ products, Recorlev and Gvoke, which have intellectual property protection until 2036 and 2040, respectively, as significant growth drivers. The company is also preparing for the Phase 3 development of XP-8121, a once-weekly levothyroxine autoinjector, which could represent a significant market opportunity. These developments reflect Xeris Pharmaceuticals’ robust performance and strategic positioning for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.